Sarepta Therapeutics, Inc. SRPT
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -45.09% | 64.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -45.09% | 64.99% | |||
| Cost of Revenue | -8.41% | -63.71% | |||
| Gross Profit | -65.69% | 266.51% | |||
| SG&A Expenses | -1.24% | -15.08% | |||
| Depreciation & Amortization | 3.76% | 2.07% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.29% | -56.35% | |||
| Operating Income | -85.41% | 187.40% | |||
| Income Before Tax | -100.51% | 223.31% | |||
| Income Tax Expenses | -74.29% | 168.40% | |||
| Earnings from Continuing Operations | -101.48% | 217.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -101.48% | 217.01% | |||
| EBIT | -85.41% | 187.40% | |||
| EBITDA | -83.01% | 191.16% | |||
| EPS Basic | -101.47% | 216.79% | |||
| Normalized Basic EPS | -89.37% | 181.19% | |||
| EPS Diluted | -101.74% | 206.48% | |||
| Normalized Diluted EPS | -87.66% | 169.92% | |||
| Average Basic Shares Outstanding | 0.42% | 0.19% | |||
| Average Diluted Shares Outstanding | -13.52% | 16.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||